New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
10:00 EDTMDLZ, RCL, TEVA, BXP, VOLC, ZIOP, XEL, SF, STX, PTEN, NVS, NOV, IEXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: IDEX Corp. (IEX) downgraded to Hold from Buy at Brean Capital... National Oilwell (NOV) downgraded to Outperform from Buy at CLSA... Novartis (NVS) downgraded to Hold from Buy at Deutsche Bank... Patterson-UTI Energy (PTEN) downgraded to Outperform from Buy at CLSA... Seagate (STX) downgraded to Underweight from Neutral at JPMorgan... Stifel Financial (SF) downgraded to Underperform from Market Perform at Wells Fargo... Xcel Energy (XEL) downgraded to Neutral from Outperform at Macquarie... Ziopharm (ZIOP) downgraded to Hold from Buy at Jefferies... Boston Properties (BXP) downgraded to Hold from Buy at Stifel Nicolaus... Volcano (VOLC) downgraded to Neutral from Outperform at Credit Suisse... Teva (TEVA) downgraded to Market Perform from Outperform at Leerink... Royal Caribbean (RCL) downgraded to Neutral from Buy at Longbow... Mondelez (MDLZ) downgraded to Hold from Buy at Argus.
News For IEX;NOV;NVS;PTEN;STX;SF;XEL;ZIOP;VOLC;BXP;TEVA;RCL;MDLZ From The Last 14 Days
Check below for free stories on IEX;NOV;NVS;PTEN;STX;SF;XEL;ZIOP;VOLC;BXP;TEVA;RCL;MDLZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 21, 2014
07:11 EDTNVSInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
07:03 EDTNVSAnacor, Sandoz enter into agreement for commercialization of Kerydin in the U.S.
Anacor Pharmaceuticals (ANAC) announced that it has entered into an exclusive agreement with Sandoz, a Novartis (NVS) company, pursuant to which Sandoz will distribute and commercialize Anacorís drug KERYDIN topical solution, 5% in the United States. PharmaDerm, the branded dermatology business of Sandoz, will be responsible for the sales and marketing of KERYDIN. On July 8, Anacor announced that the U.S. FDA approved the New Drug Application for KERYDIN, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States, according to Podiatry Today. The agreement with Sandoz entitles Anacor to upfront payments totaling $40M and an additional milestone payment of $25M expected to be paid in January 2015. Under the agreement, Sandoz and Anacor will share equally, under a long-term profit-sharing arrangement, the gross profits accrued by Sandoz on sales of KERYDIN, except that in 2015 Anacor will start receiving profit-sharing payments after the first $50M of gross profits have been accrued by Sandoz. The long-term profit-sharing arrangement includes cumulative minimum profit-sharing payments to Anacor in 2016 totaling $45M. Anacor will also have the option to repurchase all rights in KERYDIN from Sandoz on the later of three years from launch or December 31, 2017, at a price to be determined pursuant to the agreement. Under the terms of the agreement, Anacor will supply product to Sandoz at cost through Anacorís contract manufacturers, and Sandoz will be responsible for all of its selling, marketing, distribution, general and administrative costs related to the commercialization of KERYDIN. Anacor will hold the NDA and will be responsible for any further development of KERYDIN.
July 20, 2014
16:08 EDTMDLZMondelez, D.E Master consider brand sales as coffee pact looms, Reuters says
Subscribe for More Information
July 18, 2014
08:51 EDTSTXSeagate upgraded to Buy from Hold at Craig-Hallum
Subscribe for More Information
07:40 EDTSTXSeagate shares could trade as high as $100, says Brean Capital
Brean Capital remains bullish on Seagate following its Q4 results. The firm expects solid industry demand and improved gross margins and believes the company's revenue guidance is conservative. The firm has a Buy rating and $70 price target on Seagate, but said its stock could trade as high as $100 if earnings, free cash flow, and enterprise value hit the top end of its potential range.
07:25 EDTSTXWestern Digital has positive read through from Seagate results, says RBC Capital
Subscribe for More Information
July 17, 2014
18:31 EDTSTXOn The Fly: After Hours Movers
Subscribe for More Information
17:56 EDTSTXWestern Digital down 1.2% after peer Seagate reports Q4 results
17:52 EDTSTXSeagate comes off after hours lows after Q1 revenue guidance
Subscribe for More Information
17:49 EDTSTXSeagate sees Q1 revenue at least $3.55B, consensus $3.54B
Subscribe for More Information
16:09 EDTSTXSeagate falls after results, levels to watch
Subscribe for More Information
16:02 EDTSTXSeagate reports Q4 EPS $1.10, consensus $1.10
Subscribe for More Information
15:26 EDTSTXNotable companies reporting after market close
Subscribe for More Information
11:54 EDTSTXStocks with call strike movement; SNDK STX
Subscribe for More Information
08:34 EDTNVSVanda requests award of $539M in proceedings with Novartis
Subscribe for More Information
08:14 EDTSTXSeagate July weekly volatility elevated into Q2 and outlook
Seagate July weekly call option implied volatility is at 47, August is at 31, September is at 26, December is at 25; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on July 21.
05:32 EDTNVSNovartis reconfirms FY14 revenue guidance up at low to mid single digit rate
The company stated, "We are reconfirming our outlook for FY14. Group net sales in 2014 are expected to grow at a low to mid-single digit rate. Group core operating income is expected to grow ahead of sales in 2014, and now refined to mid to high-single digit. This outlook recognizes the entry of generic competition for Diovan monotherapy in the U.S. on July 7, including an authorized generic from Sandoz on the same date. If June average exchange rates prevail for the remainder of the year, the currency impact for the year would be -1% on sales and -3% to -4% on core operating income."
05:29 EDTNVSNovartis reports Q2 Core EPS $1.34, consensus $1.42
Reports Q2 revenue $14.6B, consensus $14.81B. Reports continued pipeline progress with positive regulatory decisions and significant clinical trial data released in Q2.
July 16, 2014
08:48 EDTTEVATeva says ISS supports company's nominees, shareholders' meeting proposals
Subscribe for More Information
07:09 EDTRCLRoyal Caribbean Q2 results likely to be positive catalyst, says Stifel
Stifel predicts that Royal Caribbean's Q2 results will improve sentiment towards the name, as it believes that worries about the outlook for Caribbean cruises are overdone. The firm keeps a $65 price target and Buy rating on the shares.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use